Potential risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii were investigated in a cohort study in 25 Spanish hospitals. The clonal relationship among isolates was determined by pulsed-field gel electrophoresis (PFGE). In total, A. baumannii was isolated from 203 patients, with imipenem-resistant (MIC 90 128 mg ⁄ L) isolates being obtained from 88 patients (43%), and imipenemsusceptible isolates from 115 patients (57%). A wide clonal distribution was observed among the imipenem-resistant isolates, but spread of the same clone among centres was not demonstrated. The results indicated that imipenem-resistant A. baumannii is a widely distributed nosocomial pathogen in Spain and reaches an alarming frequency in some centres. Independent risk-factors for the acquisition of imipenem-resistant A. baumannii were a hospital size of > 500 beds (multivariate OR, 6.5; 95% CI, 1.8-23), previous antimicrobial treatment (multivariate OR, 4.3; 95% CI, 1.6-11), a urinary catheter (multivariate OR, 2.7; 95% CI, 1.1-6.7) and surgery (multivariate OR, 2; 95% CI, 1.07-3.8).
I N T R O D U C T I O N
Acinetobacter baumannii is an important nosocomial pathogen in developed countries which is difficult to both control and treat because of its prolonged environmental survival and its ability to develop resistance to multiple antimicrobial agents [1, 2] . In general, imipenem is the agent most active against A. baumannii. In a study in 49 USA hospitals, in which 111 episodes of bacteraemia caused by A. baumannii were analysed, imipenem was active in vitro against all the isolates (MIC 90 1 mg ⁄ L) [3] . However, reports of imipenem-resistant A. baumannii (IMP-R A. baumannii) strains have been rising steadily during the past few years, and these isolates are often multidrug-resistant [4] [5] [6] [7] [8] . It is likely that multiple mechanisms account for carbapenem resistance in A. baumannii [9, 10] . These data are disturbing because inappropriate empirical antimicrobial treatment increases mortality in patients with bacteraemia [11, 12] .
Previous studies of risk-factors for the acquisition of IMP-R A. baumannii have focused on a single city or institution [4, 6, 7] . These studies have suggested that previous use of third-generation cephalosporins or carbapenems, admission to a ward with a high density of patients infected with IMP-R A. baumannii, and a high workload all contribute to acquisition of carbapenem-resistant A. baumannii [4, 6, 7] . Recently, a case-control study suggested that the risk-factors for nosocomial IMP-R A. baumannii infection were previous stay in an intensive care unit (ICU), and previous exposure to imipenem or third-generation cephalosporins [13] . However, more data regarding the risk-factors for IMP-R A. baumannii colonisation ⁄ infection are needed in order to prevent infection and to optimise therapy.
The present study investigated the risk-factors for the acquisition of IMP-R A. baumannii as part of a nationwide study in Spain. Genotypic analysis using pulsed-field gel electrophoresis (PFGE) was used to determine whether inter-hospital spread of imipenem-resistant isolates had occurred.
M E T H O D S Participating hospitals
Members of the Spanish Group for Nosocomial Infection (GEIH) from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) were asked to participate in the GEIH-Ab 2000 project, which was designed to investigate the epidemiology, mechanisms of resistance and clinical implications of A. baumannii in Spanish hospitals. The 28 participating hospitals serve a population of 11 million (c. 25% of the total population of Spain). Twenty-six (92.8%) of the participants were public hospitals, 14 (50%) were university hospitals, and 19 (67.8%) had active transplant programmes. Eleven (39.3%) had > 1000 beds, ten (35.7%) had 500-999 beds, and seven (25%) had < 500 beds.
Study definitions
Every new case of colonisation or infection caused by A. baumannii during November 2000 in the participating hospitals was included. For each case, only the first isolate was included.
The breakpoint for defining imipenem-susceptible A. baumannii (IMP-S A. baumannii) was an MIC £ 4 mg ⁄ L, and a breakpoint of ‡ 8 mg ⁄ L was used for IMP-R A. baumannii, i.e., intermediate and resistant isolates [14, 15] . A. baumannii was considered to be acquired nosocomially if the specimen was obtained > 2 days after the admission of the patient to hospital. The clinical significance (colonisation or infection) of each A. baumannii isolate and the type of infection were assessed according to CDC criteria [16, 17] .
Risk-factor analysis
The following data were collected: age, gender, presence or absence of underlying conditions, hospital size (i.e., > 500 or < 500 beds), type of hospital ward (ICU, medical, surgical or paediatric), treatment with antimicrobial agents, number and classes of antimicrobial agent, intravenous, arterial or urinary catheter, nasogastric tube, parenteral nutrition, mechanical ventilation, surgical procedures, and ICU and hospital stay before infection ⁄ colonisation. Patients were followed until discharge or death, or until 30 days after the specimen had been obtained if the patient was still hospitalised.
Microbiological studies
All isolates identified presumptively as A. baumannii in each participating hospital were sent to a reference laboratory (Hospital Clinic, Barcelona), where identification was performed initially with the API 20 NE system (bioMérieux, Marcy l'Etoile, France) and confirmed by amplified ribosomal DNA restriction analysis [18] .
PFGE was used to determine whether inter-hospital spread of imipenem-resistant isolates had occurred, following the methodology described by Gautom [19] , with 20 U of ApaI used for restriction endonuclease digestion. DNA fragments were separated in an agarose 1% w ⁄ v gel and electrophoresed in 0.5· Tris-borate-EDTA buffer at 6 V ⁄ cm on a contourclamped homogeneous electric field apparatus (CHEF DRIII; Bio-Rad Laboratories, Richmond, CA, USA). Pulse times were from 5 to 8 s for 20 h. The gels were stained with ethidium bromide and photographed under UV light. Isolates were assigned to clonal groups according to the criteria of Tenover et al. [20] .
Antimicrobial susceptibility to imipenem (Merck Sharp & Dohme, Madrid, Spain) was determined by microdilution following NCCLS recommendations [15] .
Statistical analysis
Data were recorded on standardised forms and entered into a database. Analyses were performed using SPSS software, v. 11.0 (SPSS Inc., Chicago, IL, USA). Categorical variables were compared by Fisher's exact test. If continuous data were distributed normally, the ANOVA ANOVA test was used; otherwise, non-parametric two-sample tests were used. Variables with a p value < 0.1 in the univariate analysis were included in the multivariate analysis. Multivariate stepwise (forward) logistic regression analysis was performed to determine independent risk-factors for acquiring imipenem resistance. The optimal variables, on the basis of clinical significance, were included in the final model. Co-linearity was discarded. All statistical analyses were two-sided, and significance was set at p < 0.05.
R E S U L T S Clinical and microbiological findings
During the study period, 240 isolates identified presumptively as A. baumannii were sent to the reference laboratory. Nineteen isolates were excluded: one was not Acinetobacter spp.; 15 were identified as Acinetobacter genospecies 3 [21] ; and three were Acinetobacter spp. other than A. baumannii. Thus, in total, 25 (89.2%) of the 28 participating hospitals had 221 patients with A. baumannii colonisation or infection during the study period. The clinical features and epidemiology of these patients, as well as the clonal diversity, antimicrobial susceptibility and type-1 integron content of the isolates, have been described previously [22] [23] [24] . The present study of risk-factors included 203 patients with A. baumannii colonisation or infection; 18 (8%) patients were excluded because of incomplete clinical records.
The MIC 50 and the MIC 90 of imipenem for the isolates were 1 and 128 mg ⁄ L, respectively. Eighty-eight isolates (43.3%) were imipenemresistant (including 13 (6.4%) with intermediate susceptibility) and 115 (56.6%) were imipenemsusceptible. The IMP-R A. baumannii isolates were more resistant to other antimicrobial agents than were the IMP-S isolates [23] . IMP-R isolates were detected in 11 (39.3%) hospitals, and IMP-S isolates in 22 (79%) hospitals. The geographical distribution of the hospitals is shown in Fig. 1 .
PFGE identified 27 different clones among the IMP-R isolates (Table 1) . No single clone was detected in more than one hospital, but 21 isolates of the same IMP-R clone (PFGE type 72) were isolated from different patients in a single hospital (no. 21), confirming intra-institutional spread.
The pooled mean incidence of IMP-R A. baumannii colonisation or infection was 1.36 cases per 1000 admissions, with a range according to centre of 0-34 (Table 1) . Patients were either colonised (51%) or infected (49%) with IMP-R A. baumannii. The types of infections and mortality rates were similar for patients with IMP-R and IMP-S A. baumannii ( Table 2 ). The overall mortality rate was 19% (39 of 203). The mortality rate of patients with infection (29 of 108; 27%) was higher than that of patients with A. baumannii colonisation (10 of 95; 11%; p < 0.01).
Risk-factors
The results of the univariate analysis revealed significant differences between the patients with IMP-R or IMP-S A. baumannii in terms of hospital size, previous ICU stay, ICU ward, previous antimicrobial treatment, number of antimicrobial 
D I S C U S S I O N
The study confirmed that IMP-R A. baumannii is an important nosocomial pathogen that is distributed widely throughout Spain. IMP-R A. baumannii was isolated in 39% of the participating hospitals. The distribution did not follow a geographical pattern; thus, some hospitals in a city had a high incidence of this pathogen, while other hospitals in the same city did not (Fig. 1 ). These differences probably reflect different patterns of antimicrobial use, epidemiological circumstances and the infection control programmes in each centre, as has been described for hospitals in Brooklyn, USA [4] . The overall incidence of IMP-R A. baumannii infection ⁄ colonisation in Spain is quite high, i.e., 1.36 cases ⁄ 1000 hospital admissions, and is also highly variable between centres (0-34 cases ⁄ 1000 hospital admissions). Although there are no similar published studies with which to compare the incidence of patients with IMP-R A. baumannii, various studies have reported that the incidence of imipenem resistance in Acinetobacter spp. is 6-8% in the USA and Canada, 10% in Latin America, and 16% in Europe [25] [26] [27] . The overall frequency of IMP-R A. baumannii in the present study was 43%, suggesting that there is room for improvement in the prevention and control measures for IMP-R A. baumannii infections in Spain.
The study showed that IMP-R A. baumannii has great clonal variability in Spain, and that polyclonal dissemination predominates. Thus, there were 27 different clones among the 88 IMP-R A. baumannii isolates. Endemic polyclonal dissemination of IMP-R A. baumannii was demonstrated in seven (64%) of 11 participating centres, while epidemic monoclonal dissemination was shown in four (36%) centres (Table 1 ). The genetic heterogeneity of IMP-R A. baumannii in Spain has been found previously at a local level in single-centre studies [6, 28] , but a nationwide study has not been performed previously. The present study did not detect inter-hospital dissemination of a single IMP-R A. baumannii clone, and nor did it detect dissemination between hospitals in a single city. These findings are in contrast with those from Brooklyn, USA, where 85% of the 275 isolates corresponded to two genotypes, and 14 of the 15 participating centres yielded isolates belonging to a single clone [9] . It has been suggested that antimicrobial resistance is the main risk-factor allowing epidemic spread of A. baumannii [29] , but it may be the local circumstances of each centre that influence the occurrence of outbreaks involving monoclonal dissemination, followed by the development of endemic polyclonal IMP-R A. baumannii infections ⁄ colonisations. Hospital size has not been described previously as a risk-factor, but this probably reflects the greater complexity of care needed by patients admitted to large hospitals, and therefore the higher numbers of patients at risk and healthcare staff. The consumption of antimicrobial agents is greater and the density of susceptible patients is higher than in small hospitals. Finally, once an epidemic has begun, it is more difficult to control. This risk-factor can be influenced by improving and intensifying the measures for prevention and control of infection in large hospitals. Antimicrobial treatment is a risk-factor that has been identified previously, with particular reference to use of third-generation cephalosporins, imipenem, aztreonam and quinolones [4, 13, 30, 31] . Previous surgery and the presence of a urinary catheter are risk-factors that reflect the high workload in a high-risk unit (surgical ICU) [7] . There is a need to distinguish between colonisation and infection (which accounted for 47% of the isolates in the present study), in order to avoid unnecessary use of antimicrobial agents.
The present study was not without limitations. The study design, comparing patients with IMP-R and IMP-S A. baumannii, could overestimate the influence of previous treatment with antimicrobial agents. The level of environmental contamination, a known risk-factor for outbreaks of A.baumannii [32] , was not analysed. Finally, as the study covered a period of 1 month, there could be seasonal variations in the incidence of infection ⁄ colonisation caused by A. baumannii. Nevertheless, the results suggest that IMP-R A. baumannii is a widely distributed nosocomial pathogen in Spain, and reaches an alarming prevalence in some centres. Acquisition of IMP-R A. baumannii is related strongly to hospital size, and may be favoured by previous surgery, the presence of a urinary catheter, and the selection pressure of treatment with an antimicrobial agent. The increase in the prevalence of this multiresistant pathogen in Spain should lead to an immediate response at the local and national levels to limit the inappropriate use of antimicrobial agents, to improve the diagnostic capacity for distinguishing between colonisation and infection, and to reinforce adherence to infection safeguard and control measures. 
